It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Spinocerebellar ataxia 1 (SCA1) is a devastating neurodegenerative disease associated with cerebellar degeneration and motor deficits. However, many patients also exhibit neuropsychiatric impairments such as depression and apathy; nevertheless, the existence of a causal link between the psychiatric symptoms and SCA1 neuropathology remains controversial. This study aimed to explore behavioral deficits in a knock-in mouse SCA1 (SCA1154Q/2Q) model and to identify the underlying neuropathology. We found that the SCA1 mice exhibit previously undescribed behavioral impairments such as increased anxiety- and depressive-like behavior and reduced prepulse inhibition and cognitive flexibility. Surprisingly, non-motor deficits characterize the early SCA1 stage in mice better than does ataxia. Moreover, the SCA1 mice exhibit significant hippocampal atrophy with decreased plasticity-related markers and markedly impaired neurogenesis. Interestingly, the hippocampal atrophy commences earlier than the cerebellar degeneration and directly reflects the individual severity of some of the behavioral deficits. Finally, mitochondrial respirometry suggests profound mitochondrial dysfunction in the hippocampus, but not in the cerebellum of the young SCA1 mice. These findings imply the essential role of hippocampal impairments, associated with profound mitochondrial dysfunction, in SCA1 behavioral deficits. Moreover, they underline the view of SCA1 as a complex neurodegenerative disease and suggest new avenues in the search for novel SCA1 therapies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Charles University, Department of Pathological Physiology, Faculty of Medicine in Pilsen, Pilsen, Czechia (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X); Charles University, Laboratory of Neurodegenerative Disorders, Biomedical Center, Faculty of Medicine in Pilsen, Pilsen, Czechia (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
2 Charles University, Department of Physiology, Faculty of Medicine in Pilsen, Pilsen, Czechia (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X); Charles University, Mitochondrial Laboratory, Biomedical Center, Faculty of Medicine in Pilsen, Pilsen, Czechia (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
3 Charles University, Laboratory of Tumor Biology, Biomedical Center, Faculty of Medicine in Pilsen, Pilsen, Czechia (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
4 Charles University, Department of Biology, Faculty of Medicine in Pilsen, Pilsen, Czechia (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
5 Charles University, Department of Pathological Physiology, Faculty of Medicine in Pilsen, Pilsen, Czechia (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
6 Charles University, Laboratory of Proteomics, Biomedical Center, Faculty of Medicine in Pilsen, Pilsen, Czechia (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)